{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:21:18Z","timestamp":1791944478185,"version":"4.3.4"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T00:00:00Z","timestamp":1696636800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"SQ Innovation, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Subcutaneous (SC) furosemide has potential advantages over intravenous (IV) furosemide by enabling self-administration or administration by a lay caregiver, such as facilitating early discharge, preventing hospitalizations, and in palliative care. A high-concentration, pH-neutral furosemide formulation has been developed for SC administration via a small patch infusor pump. We aimed to compare the bioavailability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of a new SC furosemide formulation with conventional IV furosemide and describe the first use of a bespoke mini-pump to administer this formulation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>A novel pH-neutral formulation of SC furosemide containing 80\u00a0mg furosemide in \u223c2.7\u00a0mL (infused over 5 h) was investigated. The first study was a PK\/PD study of SC furosemide compared with 80\u00a0mg IV furosemide administered as a bolus in ambulatory patients with heart failure (HF). The primary outcome was absolute bioavailability of SC compared with IV furosemide. The second study investigated the same SC furosemide preparation delivered by a patch infusor in patients hospitalized with HF. Primary outcome measures were treatment-emergent adverse events, infusion site pain, device performance, and PK measurements.<\/jats:p>\n                  <jats:p>The absolute bioavailability of SC furosemide in comparison to IV furosemide was 112%, resulting in equivalent diuresis and natriuresis. When SC furosemide was administered via the patch pump, there were no treatment-emergent adverse events and 95% of participants reported no\/minor discomfort at the infusion site.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The novel preparation of SC furosemide had similar bioavailability to IV furosemide. Administration via a patch pump was feasible and well tolerated.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvad073","type":"journal-article","created":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T11:21:40Z","timestamp":1696677700000},"page":"35-44","source":"Crossref","is-referenced-by-count":15,"title":["A novel, small-volume subcutaneous furosemide formulation delivered by an abdominal patch infusor device in patients with heart failure: results of two phase I studies"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8419-0838","authenticated-orcid":false,"given":"Joanna","family":"Osmanska","sequence":"first","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow , Glasgow G12 8TA , UK"},{"name":"Department of Cardiology, Queen Elizabeth University Hospital , Glasgow G51 4TF , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katriona","family":"Brooksbank","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow , Glasgow G12 8TA , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran F","family":"Docherty","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow , Glasgow G12 8TA , UK"},{"name":"Department of Cardiology, Queen Elizabeth University Hospital , Glasgow G51 4TF , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy","family":"Robertson","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow , Glasgow G12 8TA , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsty","family":"Wetherall","sequence":"additional","affiliation":[{"name":"Robertson Centre for Biostatistics, University of Glasgow G12 8TB , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7262-7000","authenticated-orcid":false,"given":"Alex","family":"McConnachie","sequence":"additional","affiliation":[{"name":"Robertson Centre for Biostatistics, University of Glasgow G12 8TB , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Hu","sequence":"additional","affiliation":[{"name":"Allucent , Durham, NC 27713 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy S","family":"Gardner","sequence":"additional","affiliation":[{"name":"Scottish National Advanced Heart Failure Service, Golden Jubilee National Hospital , Glasgow G81 4DY , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L","family":"Clark","sequence":"additional","affiliation":[{"name":"Department of Academic Cardiology, Hull University Teaching Hospital NHS Trust , Hull GU16 5JQ , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain B","family":"Squire","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Sciences, University of Leicester, and NIHR Cardiovascular Biomedical Research Centre, Glenfield Hospital , Leicester LE3 9QP , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R","family":"Kalra","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Queen Alexandra Hospital, Portsmouth Hospitals University NHS Trust , Portsmouth PO6 3LY , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4306-5317","authenticated-orcid":false,"given":"Pardeep S","family":"Jhund","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow , Glasgow G12 8TA , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Muntendam","sequence":"additional","affiliation":[{"name":"SQ Innovation Inc. , Burlington, MA 01803 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6317-3975","authenticated-orcid":false,"given":"John J V","family":"McMurray","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow , Glasgow G12 8TA , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6333-9496","authenticated-orcid":false,"given":"Mark C","family":"Petrie","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow , Glasgow G12 8TA , UK"},{"name":"Department of Cardiology, Glasgow Royal Infirmary , Glasgow G40SF , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0050-2129","authenticated-orcid":false,"given":"Ross T","family":"Campbell","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow , Glasgow G12 8TA , UK"},{"name":"Department of Cardiology, Queen Elizabeth University Hospital , Glasgow G51 4TF , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,10,6]]},"reference":[{"key":"2024010504415436900_bib1"},{"key":"2024010504415436900_bib2","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/jvp.13009","article-title":"Pharmacokinetics of furosemide in goats following intravenous, intramuscular, and subcutaneous administrations","volume":"44","author":"Cetin","year":"2021","journal-title":"J Vet Pharmacol Ther"},{"key":"2024010504415436900_bib3","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/jvp.12937","article-title":"Pharmacokinetics and bioavailability of furosemide in sheep","volume":"44","author":"Durna Corum","year":"2021","journal-title":"J Vet Pharmacol Ther"},{"key":"2024010504415436900_bib4","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/1541931213571042","article-title":"The system usability scale: beyond standard usability testing","volume":"57","author":"Grier","year":"2013","journal-title":"Proc Hum Factors Ergon Soc Annu Meet"},{"key":"2024010504415436900_bib5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10741-018-9760-6","article-title":"Subcutaneous furosemide for the treatment of heart failure: a state-of-the art review","volume":"24","author":"Afari","year":"2019","journal-title":"Heart Fail Rev"},{"key":"2024010504415436900_bib6","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/ehf2.12677","article-title":"Outpatient treatment of worsening heart failure with intravenous and subcutaneous diuretics: a systematic review of the literature","volume":"7","author":"Wierda","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2024010504415436900_bib7","doi-asserted-by":"crossref","first-page":"e763","DOI":"10.1136\/bmjspcare-2019-002158","article-title":"Furosemide in end-stage heart failure: community subcutaneous infusions","volume":"12","author":"Brown","year":"2020","journal-title":"BMJ Support Palliat Care"},{"key":"2024010504415436900_bib8","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.nefro.2017.09.001","article-title":"Palliative use of furosemide in continuous subcutaneous infusion in a renal transplant patient with heart failure","volume":"38","author":"Picazo S\u00e1nchez","year":"2018","journal-title":"Nefrologia"},{"key":"2024010504415436900_bib9","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1177\/0269216311399490","article-title":"Is there a role for subcutaneous furosemide in the community and hospice management of end-stage heart failure?","volume":"25","author":"Zacharias","year":"2011","journal-title":"Palliat Med"},{"key":"2024010504415436900_bib10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jacbts.2017.10.001","article-title":"Subcutaneous furosemide in heart failure: pharmacokinetic characteristics of a newly buffered solution","volume":"3","author":"Sica","year":"2018","journal-title":"JACC Basic Transl Sci"},{"key":"2024010504415436900_bib11","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jchf.2017.10.001","article-title":"Efficacy of intravenous furosemide versus a novel, pH-neutral furosemide formulation administered subcutaneously in outpatients with worsening heart failure","volume":"6","author":"Gilotra","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2024010504415436900_bib12","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jama.1967.03120240107021","article-title":"Furosemide (Lasix)","volume":"200","author":"Evaluation of a new oral diuretic agent","year":"1967","journal-title":"JAMA"},{"key":"2024010504415436900_bib13","article-title":"Furosemide Injection (furosemide), for intravenoue or intramuscular use","author":"Food and Drug Administration"},{"key":"2024010504415436900_bib14","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1056\/NEJMoa1005419","article-title":"Diuretic strategies in patients with acute decompensated heart failure","volume":"364","author":"Felker","year":"2011","journal-title":"N Engl J Med"},{"key":"2024010504415436900_bib15","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s40273-020-00952-0","article-title":"A systematic review of medical costs associated with heart failure in the USA (2014-2020)","volume":"38","author":"Urbich","year":"2020","journal-title":"Pharmacoeconomics"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvad073\/53167749\/pvad073.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/10\/1\/35\/55013869\/pvad073.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/10\/1\/35\/55013869\/pvad073.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T05:06:23Z","timestamp":1704431183000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/10\/1\/35\/7296123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,6]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,10,6]]},"published-print":{"date-parts":[[2024,1,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvad073","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1]]},"published":{"date-parts":[[2023,10,6]]}}}